A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and...
Johnson & Johnsontoday published its2022 Health for Humanity Report, which serves as its annual disclosure on environmental, social and governance (ESG) performance. The Report also provides progress against our ambitious set of Health for Humanity 2025 Goals. In 2022, ...
2023 Annual Report 2022 Annual Report 2021 Annual Report 2020 Annual Report 2019 Annual Report 2018 Annual Report 2017 Annual Report 2016 Annual Report 2015 Annual Report 2014 Annual Report 2013 Annual Report 2012 Annual Report 2011 Annual Report...
A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and ...
s Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly...
Company Research Report: Johnson & Johnson. Company details, financials, key personnel, industries of involvement, service providers and more. Download instantly.
Duato said the strong pharmaceutical results and potential upcoming drug launches make J&J “very confident” it can meet the division’s 2025 annual sales target of $57 million. Kenvue results, talc litigation J&J said the consumer health business raked in $4.01 billion in sales for the quarter...
Johnson Matthey has published itsAnnual Report and Accounts 2022. In it we share financial and non-financial performance for the year ended March 2022, our reinvigorated strategy and an update on our sustainability commitments. Our vision for a cleaner, healthier world drives our strategy to catalys...
Following the completion of the transaction, Abiomed will operate as a standalone business within Johnson & Johnson MedTech, becoming one of 12 JJMT priority platforms as defined by annual sales of at least $1 billion each. Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive...
Annual Report 2018 2017/18 was a good year for JM. We delivered what we said we would, and built foundations for future growth. Download the full report (PDF, 13MB) Full year results announcement Investing in our science World class science and technology is at our core. In a world ...